Learn About Sentynl Therapeutics
A word from Sentynl Therapeutics, VOC’s 2023 Spring Tea Presenting Sponsor:
Sentynl Therapeutics is excited and honored to support The Vision of Children Foundation 2023 “Sip to SEE, Springtime Tea” as a Presenting Sponsor. The Foundation’s efforts to cure genetic vision disorders and childhood blindness hit close to home for us, as a company focused on bringing innovative therapies to patients with rare diseases, including those that are genetic and affect the youngest patients.
Founded in Solana Beach, California, in 2015, Sentynl is dedicated to ensuring that no patient is overlooked. As the Vision of Children founders Sam and Vivian Hardage know personally from their son’s diagnosis with a rare genetic eye disease, a potential treatment means everything but can feel far out of reach. We believe all serious diseases should be examined with the goal of finding treatments that provide meaningful improvements to patients’ lives.
Our portfolio of biopharmaceuticals is designed to address a variety of rare diseases that can have serious consequences for patients and their caregivers.
Our lead therapy is the first and only FDA-approved therapy indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. MoCD Type A is an ultra-rare, life-threatening genetic disorder that presents shortly after birth and progresses rapidly, causing irreparable damage and often leading to an early death, with a median survival age of 3 years old.
Additionally, CUTX-101 (copper histidinate) is in development to restore copper homeostasis and maintain copper levels in patients with Menkes disease and related disorders. Menkes disease is an X-linked recessive rare genetic pediatric disorder that, if untreated, can often lead to death between 6 months and 3 years old. Currently, there is no FDA-approved treatment for Menkes disease and related disorders in copper metabolism.
Although the current reality of rare and genetic disorders can be disheartening, we see opportunity for change, particularly through advancing genetic testing and enhancing newborn screening, so patients can receive a successful diagnosis faster. We deeply appreciate organizations who are furthering disease awareness, education and research, such as the Vision of Children Foundation. They are working to change our realities while supporting patients and caregivers during their diagnosis or treatment journeys.
Our team looks forward to joining the Vision of Children Foundation’s passionate community at this year’s Springtime Tea, where we’ll celebrate successes and chart the course for future progress. To learn more about Sentynl, visit our website and follow us on LinkedIn to stay in touch.